Draft lipid modification guidance issued last week by NICE recommends the use of QRISK over the currently used Framingham tool, which is known to overestimate cardiovascular risk in the UK population.
Despite this, Professor Julia Hippisley-Cox, co-author of QRISK and a GP in Nottingham, said QRISK will boost, rather than reduce, the number of patients taking statins.
‘QRISK will increase the number of patients from deprived areas and the number of women that will require statins,'she explained.
‘Patients that have already been identified as being at high risk of cardiovascular disease (CVD) will remain on statins, so QRISK will not take any patients off statins.'
Dr Terry McCormack, chairman of the Primary Care Cardiovascular Society (PCCS) and a GP in Whitby, said statin prescribing for primary prevention is underused in the UK.
Comment below and tell us what you think